Ibogaine for Opioid Addiction: Legal Status, Heart Risks, and What the Evidence Shows

What is ibogaine?

Ibogaine is a psychedelic compound found in the root bark of Tabernanthe iboga, a shrub native to Central West Africa. It has been used for centuries in Bwiti ceremonies in Gabon. Its reputation in addiction treatment dates to the 1960s, when people who took it reported that their opioid withdrawal and cravings dropped sharply afterward.

A single large dose produces a long, dream-like state that can last a day or more, usually with vomiting and loss of coordination. The liver turns ibogaine into noribogaine, which stays in the body much longer than ibogaine itself. That long tail is part of why researchers are interested in it, and part of why the heart risk does not end when the experience does.

Ibogaine vs buprenorphine vs methadone vs naltrexone

Only one of these is illegal and unapproved. The other three are FDA-approved for opioid use disorder, covered by NJ FamilyCare, and available in New Jersey now.

Is ibogaine legal in the United States?

No. Ibogaine is listed in Schedule I of the federal Controlled Substances Act, under hallucinogenic substances (DEA drug code 7260, 21 CFR 1308.11(d)). Schedule I means federal law treats it as having a high potential for abuse and no currently accepted medical use. It is illegal to make, sell, or possess outside DEA-registered research, and that includes New Jersey, which has no state law that carves out ibogaine.

It is also not approved by the FDA for opioid use disorder or anything else. No company has completed the trials the FDA requires. In April 2026 an executive order told the FDA and DEA to set up a Right to Try pathway to investigational psychedelics, including ibogaine compounds, for eligible patients. That points toward a research and access route. It did not reschedule ibogaine, and it did not make clinic ibogaine legal to buy or use. A few states have also moved to fund research (covered below), but funding a trial does not make the drug legal to use.

Colorado is the one partial exception at the state level. Its 2022 Natural Medicine Health Act removed state penalties for adults 21 and older who possess and use ibogaine personally, and a 2026 law, HB26-1325, set up a state research pilot of up to five sites, contingent on grants and donations. None of that changes federal law, and none of it applies in New Jersey.

Is ibogaine legal in Mexico?

Clinics in Mexico, and in a few other countries, openly advertise ibogaine treatment. Being openly advertised is not the same as being approved or inspected. These clinics sit outside U.S. law and outside the FDA, the DEA, and New Jersey’s licensing system for addiction treatment, so there is no U.S. agency checking the dose, the screening, the cardiac monitoring, or what happens when something goes wrong. We do not list or recommend any clinic.

Ibogaine side effects and deaths: the heart problem

The main danger is to the heart. Ibogaine slows the heart’s electrical recovery between beats, which shows up on an EKG as a longer QT interval. A long enough QT interval can tip into a chaotic rhythm called torsades de pointes, which can cause fainting and sudden death.

The best measured example comes from a Dutch university hospital, where 14 people with opioid use disorder were given one dose of ibogaine under continuous monitoring. In the 2022 study in Addiction, the corrected QT interval rose by an average of 95 milliseconds at its peak, and half the participants passed 500 milliseconds, a level cardiologists treat as a serious warning sign. Slow heart rate was common. The changes reversed and no one developed torsades, but this was in a hospital, with screened patients and cardiac monitoring the whole time.

Deaths outside that kind of setting are documented. A 2012 forensic review found 19 known deaths outside West Central Africa from 1990 through 2008, in people aged 24 to 54, between 1.5 and 76 hours after taking ibogaine. Where autopsy data were good enough to judge (14 cases), pre-existing medical problems, mostly heart disease, or other drugs explained or contributed to 12 of the deaths. The authors also flagged seizures from alcohol or benzodiazepine withdrawal as a risk. In plain terms: the people most likely to seek ibogaine, with heavy opioid, alcohol, or sedative use and untreated health problems, are the people it is most dangerous for.

The risk also does not end with the trip. In the Dutch study, 6 of the 14 patients still had a QT interval above 450 milliseconds more than 24 hours after the dose, and every patient had severe, temporary loss of coordination and could not walk without support. A person who seems fine the next morning is not yet out of the window.

Does ibogaine work for opioid addiction?

Nobody knows yet. The studies so far suggest a real effect on withdrawal and, for some people, on drug use afterward. None of them can show that ibogaine caused the change, because none compared people who got ibogaine with similar people who did not.

The two most cited opioid studies are both small and observational. In one, 30 people with opioid dependence, most of whom had already tried treatment several times, were followed for a year after ibogaine. Withdrawal scores fell by about half within a few days, and 15 of the 30 reported no opioid use in the month after treatment, according to Brown and Alper (2018). In the other, from New Zealand, 14 people were treated and only 8 completed every follow-up interview; their drug-use scores were lower at 12 months. One person enrolled in that study died during treatment, as Noller and colleagues (2018) report.

Those are encouraging signals and weak evidence. People who travel for ibogaine are highly motivated, follow-up is spotty, and there is no comparison group. The approved medications below were held to a higher standard: randomized trials and large population studies tying them to fewer overdose deaths.

The Stanford veterans study

The study behind most recent headlines is a 2024 Stanford paper in Nature Medicine. Thirty male U.S. Special Operations veterans with mostly mild traumatic brain injuries received ibogaine together with magnesium, which was meant to protect the heart, at a treatment program in Mexico. The researchers measured large improvements in disability, PTSD, depression, and anxiety one month later and reported no unexpected or serious adverse events.

Its limits matter as much as its results. It was open-label, with no placebo or comparison group, 30 participants, all men, and follow-up of only one month. It studied brain injury and related symptoms, not opioid use disorder. People with a history of heart, liver or kidney problems were excluded, so it says little about the patients most at risk. The paper’s competing-interests statement discloses that three authors are shareholders in Ambio Life Sciences, the company that offers ibogaine treatment and treated the participants in Mexico, and that several authors are inventors on patent applications related to the protocol or to ibogaine therapy. The authors themselves write that controlled trials are needed to validate these initial open-label findings.

Who is paying for ibogaine research?

Several states have put public money toward ibogaine studies, mostly for brain injury, PTSD, and addiction. What each state did differs, so the details matter.

Texas. A 2025 law, Senate Bill 2308, provided $50 million in matching state funds for an ibogaine clinical trial run by a public university with a hospital and a drug company. In December 2025 the Texas Health and Human Services Commission awarded the money to UTHealth Houston and UTMB Health, whose announcement lists addiction, traumatic brain injury, PTSD, and other behavioral health conditions as targets and says the goal is FDA approval.

Arizona. The 2025 budget set aside $5 million for a certified clinical study of ibogaine for neurological disease, including brain injury and PTSD (HB 2871). In August 2026 the state awarded the grant to Barrow Neurological Institute and Arizona State University for a 40-person trial in people with chronic brain injury symptoms, with research planned to begin in 2027.

Kentucky. In 2023 the leader of the state’s opioid settlement commission proposed spending $42 million of settlement money on ibogaine research. In 2024 the new attorney general, Russell Coleman, asked the commission to step back from the plan, calling it an unproven and costly trial, and suggested a smaller $5 million innovation grant fund instead. Kentucky backed away from the $42 million plan.

Colorado is covered above: its 2026 pilot depends on donations and grants, not state appropriations.

Notice what these have in common. They fund studies. Brain injury and PTSD are the main targets in Arizona and the Stanford work, and the Texas trial lists addiction among several conditions. Until results are in, none of this makes ibogaine a treatment for opioid use disorder.

Why unregulated ibogaine clinics are risky

The Dutch hospital study shows what careful ibogaine treatment looks like: screened patients, continuous heart monitoring, and staff ready to treat a dangerous rhythm. Even there, half the patients crossed a QT level cardiologists treat as a serious warning sign. A clinic abroad may or may not screen for heart disease, check electrolytes, ask about every other drug a person takes, or have a defibrillator and trained staff at the bedside. From the U.S., there is no reliable way to know.

The deaths in the forensic review clustered in exactly the people most likely to go: those with heart disease, heavy use of other drugs, or alcohol or sedative dependence that can cause seizures when stopped. A person who stops opioids for ibogaine also comes home with lower tolerance. If they use again at their old amount, the overdose risk is the same one every detox warns about.

Treatment that works for opioid addiction in New Jersey

Three medications are FDA-approved for opioid use disorder, and all three are available in New Jersey now: buprenorphine, methadone, and extended-release naltrexone. Our buprenorphine comparison and medication guide explain how each one works. People who stayed on methadone or buprenorphine died of overdose at several times lower rates than people who had left it, according to a 2017 BMJ meta-analysis of cohort studies.

Withdrawal is usually where people get stuck, and it is treatable. Medical detox uses buprenorphine or methadone to control withdrawal and cravings, plus other medications for sleep, nausea, and diarrhea; our opioid detox guide covers it, and the list of licensed detox programs in New Jersey shows where to go by county.

In New Jersey

Fully insured New Jersey plans and the State Health Benefits and School Employees’ plans cannot require prior authorization for the first 180 days per plan year of in-network treatment your own physician, psychologist or psychiatrist finds medically necessary. Self-funded employer plans, Medicare and Medicaid are not covered by that rule. NJ FamilyCare (Medicaid) members and people without insurance can call the IME Addictions Access Center at 1-844-276-2777, which screens callers and refers them to treatment. ReachNJ, at 1-844-732-2465, is the state’s treatment referral line. Both answer 24/7. Same-day admission is sometimes possible; it is not guaranteed. For what a specific plan covers, see the insurance guides.

Under the state’s Naloxone365 program, anyone 14 or older can get naloxone anonymously at participating pharmacies; StopOverdoses.nj.gov lists them.

Periscope Behavioral Health, which publishes this site, is opening a medical detox in Hammonton, Atlantic County, expected Summer 2027. Until then, the admissions line of our publisher, Periscope Behavioral Health, at (888) 313-3583, can talk through options in New Jersey and Florida, including facilities Periscope operates. What a plan covers depends on the plan and the facility’s network status.